Facebook
Twitter
LinkedIn
Forward42nd Annual Carrell Krusen Neuromuscular Symposium (RP2002B)
This symposium is a clinical education experience for members of multidisciplinary teams who care for patients with rare, complex neuromuscular diseases including hereditary muscular dystrophies, motor neuron diseases, neuroimmunologic neuropathies and rare genetic disorders of muscle and nerve. The 2020 keynote speaker will present data from the latest clinical trials for Duchenne muscular dystrophy and discuss new approaches for combination therapy in those patients. Case presentations will include physical diagnosis and discussion of management and new therapies by participating experts. All discussions involve active participation by attendees. The educational format for this activity includes didactic lectures with in depth Q&A, panel discussions, and powerpoint presentations. The content of the program is identified and developed through a Call for Abstracts process.
Target Audience
This program is specifically designed for Primary Care providers, Neurologists, NPs, PAs, and Researchers that desire to gain advanced knowledge in diagnosis and management of patients with neuromuscular disease.
Learning Objectives
- Recognize and manage patients with neuromuscular junction disorders at all ages.
- Discuss recent advances in the genetic diagnosis of neuromuscular disorders, in research and clinical practice and the latest developments in treatment such as gene replacement therapy.
- Identify and apply current pharmacological and non-pharmacological treatments in motor neuron diseases including gene replacement therapy.
- Recognize the clinical applications of testing in neuromuscular disorders (to include histopathology).
- Diagnose and manage rare and complex neuromuscular diseases.
The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas Southwestern Medical Center designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.